Programme
summary
Monday
Tuesday
Wednesday
thursday
social
focus home

Thursday 15th May

0800-0845 Workshops

(sponsored by Roche)

What is new for diarrhoea? (W15)
Dr A Duncan, Glasgow

Fasting or postprandial glucose? (W16)
Dr E Kilpatrick, Hull

Obesity hormones (W17)
Dr L Ranganath, Liverpool

Copper disorders (W18)
Dr G Gillett, Sheffield

Which coronary risk factor table? (W19)
Dr P D Giles, Walsall

Vasculitis, which antibody? (W20)
Dr P Wood, Leeds

Metabolic acidosis (W21)
Dr J Hooper, London

0900-0945 Flynn Lecture

(sponsored by the Royal College of Pathologists)

Chair: Prof J C E Underwood, President, Royal College of Pathologists

A population-based examination of repeat laboratory testing
Dr C van Walraven, Ontario, Canada

1000-1200 Pathology & Politics

(sponsored by Abbott Diagnostics)

Chair: Ms J Wallace, Chief Executive, Christie Hospital, Manchester

NICE and diagnostics
Mr A Dillon, National Institute for Clinical Excellence, London

Revalidation (including scientists)
Dr Clair du Boulay, Royal College of Pathologists

Role of the MDA as a regulator
Dr Sue Ludgate, MDA

Commissioning pathology by PCTs
Dr R Cooling, Merton

1000-1200 Patient Centred Diagnostics

(sponsored by Nova Biomedical)

Chair: Mrs Doris-Ann Williams, Director-General, BIVDA

An American approach to POCT
Dr P Santrach, Mayo Clinic, USA

Do RCTs for POCT justify their use?
Dr J Kendall, Bristol

Evaluating requirement and introduction of POCT
Dr J Pearson, Leeds

POC in the pharmacy
Mr A Burr, Royal Pharmaceutical Society

1000-1200 Free Communications: Clinical Audit Symposium

Chairs: Dr K Griffiths, Ysbyty Gwynned & Dr J Barth, Leeds Teaching Hospitals Trust

An audit of oral glucose tolerance tests requests
Dr S Frost, Haywards Heath

CRP: causing renal problems
Dr P Das, Margate

Assessment of lipid-profile service in North-West and Mersey regions of England
Dr A N Hassan, Bolton

Tumour markers: their use and misuse by clinicians
Dr E S Kilpatrick, Hull

Can the addition of interpretative comments influence outcome? an example involving patients taking thyroxine
Dr E S Kilpatrick, Hull

A survey of availability of toxicological investigations in clinical biochemistry departments in Scotland
Dr M A Pollock, Glasgow

Wessex chemical pathology audit on the interpretation of serum cortisol levels
Dr A E Armston, Southampton

Are interpretative comments on clinical chemistry reports perceived by users as useful?
Dr P Mckenna, North Shields

1200-1300 Lunch in the Great Northern Hall

1200-13.30 Introduction of New Diagnostic Testing

(sponsored by Bayer)

Chair: Dr D J Wright, Northwick Park Hospital

How BNP was born at Bayer
Ms L Foohy, Tarrytown, USA

Putting natriuretic peptides into clinical practice
Dr T McDonagh, Glasgow

1315-1400 Attended Poster Session

(sponsored by Abbott Diagnostics)

1400-1530 Big is Better

(sponsored by Olympus)

Chair: Dr I Hanning, Hull Royal Infirmary

Specialist services
Prof C Self, Newcastle upon Tyne

Clinical communications and the internet: experience from Denmark
Mr C Deudal Pedersen, Odense, Denmark

Professional specialisation
Dr G Beastall, Glasgow

1400-1530 Primary Care

(sponsored by Roche)

Chair: Dr W S Smellie, Bishop Auckland General Hospital

Primary care, NSF and the laboratory
Dr R Young, Salford

Clinical utility of LFTs
Dr S Ryder, Nottingham

Decision support for primary care
Dr M van Wijk, Rotterdam, The Netherlands

1400-1530 Clinical Risk

(sponsored by Olympus)

Chair: Dr M Bosomworth, Leeds Teaching Hospitals trust

Boundaries of responsibility
Prof J Underwood, President, Royal College of Pathologists

Clinical incident reporting
Chief Executive, National Patient Safety Agency, London

No risk management . . . ?
Mr S Myerson, Barrister-at-law, Leeds

1545-1630 Foundation Award

Chair: Prof A Shenkin, President, Association of Clinical Biochemists

The challenge of delivering effective pathology services
Dr I Barnes, Leeds

1630-1645 Closing Ceremony

and announcement of Bayer Award and DPC Poster Prize